American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therape
暂无分享,去创建一个
Marc P. Bonaca | E. Antman | D. Morrow | S. Murphy | E. Braunwald | S. Wiviott | C. Ruff | Marc P Bonaca | Christian T Ruff
[1] S. Pocock,et al. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial , 2010, Circulation.
[2] F. Werf. Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. , 2010 .
[3] A. Kastrati,et al. Cangrelor - a champion lost in translation? , 2009, The New England journal of medicine.
[4] E. Unger,et al. Weighing benefits and risks--the FDA's review of prasugrel. , 2009, The New England journal of medicine.
[5] Tobias Reichlin,et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.
[6] E. Antman,et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myo , 2009, American heart journal.
[7] A. Jaffe,et al. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. , 2009, American heart journal.
[8] J. Alpert,et al. Implications of the universal definition of myocardial infarction , 2008, Nature Clinical Practice Cardiovascular Medicine.
[9] P. Jarolim,et al. Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[10] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[11] D. Morrow,et al. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. , 2007, American journal of clinical pathology.
[12] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[13] M. Burritt,et al. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. , 2006, European heart journal.
[14] I. Porto,et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.
[15] J. Ioannidis,et al. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.
[16] R. Bonow,et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. , 2003, American heart journal.
[17] E. Topol,et al. Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.
[18] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[19] R. Califf,et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. , 2000, JAMA.
[20] R. Califf,et al. Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .
[21] E. Topol,et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.
[22] A. Ibrahim,et al. Acute myocardial infarction. , 2014, Critical care clinics.
[23] Anders Hamsten,et al. 70 – Atherosclerosis, Thrombosis, and Vascular Biology , 2012 .
[24] J. Alpert,et al. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .
[25] D. Ardissino,et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.
[26] Samin K. Sharma,et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. , 2004, The American journal of cardiology.